Zanidatamab, a novel bispecific antibody that targets two HER2 epitopes similarly to trastuzumab and pertuzumab, reported an interim ORR of 41.3% and a median OS of 15.5 months in a phase I trial enrolling 17 patients with advanced HER2-positive CCA [149]. This evidence concerns the gene ERBB2 and cholangiocarcinoma.